Luc Friboulet

Luc Friboulet

UNVERIFIED PROFILE

Are you Luc Friboulet?   Register this Author

Register author
Luc Friboulet

Luc Friboulet

Publications by authors named "Luc Friboulet"

Are you Luc Friboulet?   Register this Author

33Publications

1779Reads

25Profile Views

The "Guardian of the Genome"-An Old Key to Unlock the ERCC1 Issue.

Clin Cancer Res 2019 Apr 6;25(8):2369-2371. Epub 2019 Feb 6.

INSERM U981, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/107
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-18-4123DOI Listing
April 2019

Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?

Nat Rev Clin Oncol 2018 11;15(11):694-708

INSERM U981, Gustave Roussy Cancer Campus, Université Paris Saclay, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-018-0081-4DOI Listing
November 2018

BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall.

Cancer Treat Rev 2018 May 24;66:82-94. Epub 2018 Apr 24.

Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2018.04.006DOI Listing
May 2018

A novel antibody-based approach to detect the functional ERCC1-202 isoform.

DNA Repair (Amst) 2018 04 11;64:34-44. Epub 2018 Feb 11.

INSERM U981, Gustave Roussy, 94805, Villejuif, France; Faculté de médecine, Université Paris-Sud, 94270, Kremlin-Bicêtre, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.dnarep.2018.02.002DOI Listing
April 2018

Lorlatinib in ALK- and ROS1-positive NSCLC: the future has a start.

Transl Lung Cancer Res 2018 Apr;7(Suppl 2):S103-S106

INSERM, U981, Gustave Roussy Cancer Campus, Université Paris Sud, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tlcr.2018.02.04DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943229PMC
April 2018

Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition.

Cancer Treat Rev 2017 Apr 12;55:83-95. Epub 2017 Mar 12.

Medical Oncology Unit, Univeristy Hospital of Parma, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2017.02.010DOI Listing
April 2017

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.

N Engl J Med 2016 Jan 23;374(1):54-61. Epub 2015 Dec 23.

Massachusetts General Hospital Cancer Center (A.T.S., L.F., J.F.G., L.D., R.L.F., K.R.S., J.L., G.G., J.A.E.) and the Department of Pathology (A.J.I., L.L., G.G.), Massachusetts General Hospital, Boston, and the Broad Institute of the Massachusetts Institute of Technology and Harvard, Cambridge (I.L., G.G.) - all in Massachusetts; Pfizer Worldwide Research and Development, La Jolla, CA (S.B., A.B., B.J.B., Y.-L.D., W.L., L.P.J., T.S., S.T., M.M., T.W.J.); and the Japanese Foundation for Cancer Research, Tokyo (R.K.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1508887DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4773904PMC
January 2016

Therapeutic management of ALK+ nonsmall cell lung cancer patients.

Eur Respir J 2015 Jul 30;46(1):230-42. Epub 2015 Apr 30.

Dept of Cancer Medicine, Gustave Roussy, Villejuif, France Paris-Sud University, Paris, France

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1183/09031936.00236414DOI Listing
July 2015

Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.

Clin Cancer Res 2015 Jan 28;21(1):166-74. Epub 2014 Oct 28.

Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan. Department of Medical Genome Science, Graduate School of Frontier Science, The University of Tokyo, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/content/early/2014/12/
Web Search
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-14-1385DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4286456PMC
January 2015

Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.

Clin Cancer Res 2014 Nov 16;20(22):5686-96. Epub 2014 Sep 16.

Massachusetts General Hospital Cancer Center, Charlestown, Massachusetts. Department of Medicine, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-1511DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4233168PMC
November 2014

ERCC1 function in nuclear excision and interstrand crosslink repair pathways is mediated exclusively by the ERCC1-202 isoform.

Cell Cycle 2013 Oct 9;12(20):3298-306. Epub 2013 Sep 9.

Gustave Roussy; Villejuif, France; INSERM, U981; IRCIV; Villejuif, France; Département Hospitalo-Universitaire Thorax Innovation (DHU TORINO); Villejuif, France; Université Paris Sud; Kremlin-Bicêtre, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cc.26309DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3885640PMC
October 2013

Poly(I:C) induces intense expression of c-IAP2 and cooperates with an IAP inhibitor in induction of apoptosis in cancer cells.

BMC Cancer 2010 Jun 24;10:327. Epub 2010 Jun 24.

Univ Paris-Sud, CNRS-UMR 8126 and Institut de Cancérologie Gustave Roussy, 39 rue Camille Desmoulins, F-94805 Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1471-2407-10-327DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2928000PMC
June 2010